Showing 120 of 120on this page. Filters & sort apply to loaded results; URL updates for sharing.120 of 120 on this page
HARPOON THERAPEUTICS: New data on HPN328 T cell engager at ESMO 2023 ...
Harpoon Presents Interim Data of T-Cell Engager HPN328 Clinical Trial
HPN328 / Harpoon Therap
Harpoon Therapeutics Webcast Reviewing HPN328 Interim Data
HPN328 Shows Clinical Activity and Tolerability in Neuroendocrine ...
Interim phase 1 results show HPN328 is well tolerated and clinically ...
First Patients With SCLC to Receive HPN328 Plus Tecentriq in Phase 1/2 ...
Harpoon: HPN328 Data 1st In Half Of 2024 Makes This A Must Watch ...
HPN328 Elicits Antitumor Activity in Small Cell Lung Cancer and Other NETs
Triple Twist HPN328 | jaslin-nz
Hpn328 (Anti-CD3e & DLL3 & Serum Albumin) | CD markers | 现货供应 | 美国品牌 ...
Pharma Jonpi .: HPN328 Elicits Antitumor Activity in Small Cell Lung ...
DLL3 – A Breakthrough Target for Small Cell Lung Cancer Therapy-DIMA ...
Harpoon更新BCMAxCD3和DLL3xCD3临床数据，股价涨幅20% 追溯 2022年5月中旬，Harpoon更新了主要管线 ...
ASCO GU 2024: Interim Results from a Phase 1/2 Study of HPN328, a Tri ...
Slide 3
Slide 14
6.8亿美元！默沙东收购Harpoon Therapeutics医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
Slide 27
Slide 15
HPN328, a Trispecific T Cell–Activating Protein Construct Targeting ...
Harpoon Therapeutics Inc.: Harpoon Therapeutics to Host Webcast ...
#hpn328 #immunooncology #tcell #cancer #biotech #ascogu2024 | Harpoon ...
速递 | 默沙东近7亿美元囊获临床期多特异性抗体疗法，扩展肿瘤学管线_腾讯新闻
Harpoon Therapeutics is Developing TriTAC T cell Engagers
HPN328, a tri-specific T-cell engager, in SCLC and neuroendocrine ...
Harpoon Therapeutics logo in transparent PNG format
Harpoon Therapeutics, Inc. (哈普恩治疗公司) - 药物管线_专利_临床试验_投融营收_最新药物:HPN-328 ...
Merck Successfully Acquires Harpoon Therapeutics, Inc.
Therapy considerations in neuroendocrine prostate cancer: what next? in ...
Harpoon Therapeutics, Inc. (哈普恩治疗公司): 药物管线_专利_临床试验_投融营收_最新药物:HPN-536 ...
三特异性抗体研发现状_细胞_疗法_位点
Merck brings Harpoon Therapeutics and its PhI/II T cell engager into ...
Harpoon Therapeutics logo in transparent PNG and vectorized SVG formats
Abstract 5070: Anti-tumor activity of HPN328, a DLL3-targeting tri ...
APCCC 2024: How to Treat Men with Aggressive Variant or Neuroendocrine ...
Slide 7
$HARP's third quarter 2023 results and highlights | Harpoon ...
默沙东着力布局CD3双抗，6.8亿美元收购Harpoon Therapeutics
Slide 4
Slide 13
文献解析|HPN328：靶向DLL3阳性实体瘤的三特异性T细胞激活蛋白的创新机制与临床转化前景
Merck completes Harpoon Therapeutics acquisition
DLL3靶点介绍及药物研究进展-缔码生物
Merck compra a farmacêutica Harpoon Therapeutics. | Flávio Cerqueira ...
Harpoon Therapeutics, Inc. - ROE
Slide 29
Exploring the Latest Trispecific Antibody Fusion Protein Deal by ...
Slide 8
Harpoon Therapeutics (NASDAQ: HARP) stock to rise 1,000% at the open ...
Slide 5
Updated results from a phase 1/2 study of HPN328, a tri-specific, half ...
HPN328, a new T cell–activating construct for treating solid tumors ...
Abstract C033: HPN328: An anti-DLL3 T cell engager for treatment of ...
By IPP Bureau | January 10, 2024
TriTAC®技術とHPN328｜Chiku-note.
Patented AI Platform Identifies Promising Early-Stage BioPharma Assets ...
10-K
Slide 20
698P Interim results from a phase I/II study of HPN328, a tri-specific ...
海外New things | 默克公司6.8亿美元收购Harpoon Therapeutics，进一步实现肿瘤产品线多元化-36氪
MSD adquirirá Harpoon Therapeutics, diversificando ainda mais o ...
Merck Completes Acquisition of Harpoon Therapeutics
Merck Completes Acquisition of Harpoon Therapeutics, Inc. | American ...
2024 NASDAQ:HARP 주가(Harpoon Therapeutics) 하푼 테라퓨틱스 리더십 팀 강화 - 미래로닷컴
Merck's $680 Million Strategic Move to Boost Oncology Pipeline with ...
HPN328: An Anti-DLL3 T Cell Engager for Treatment of Small Cell Lung ...
656 A phase 1/2 trial in progress of MK-6070 (aka HPN328), a DLL3 ...
研究报告 | 靶向DLL3药物在研现状|细胞|表达|临床|肿瘤|治疗|-健康界
Slide 35
MSD расширит портфель онкопрепаратов с покупкой Harpoon Therapeutics за ...
Merck to acquire Harpoon Therapeutics in $680 million deal | Companies ...
Merck to Acquire Harpoon Therapeutics | American Pharmaceutical Review ...
Effect of PDL-1 expression on prognosis in head and neck squamous cell ...
Slide 25
Biomedicines | Free Full-Text | Bi- and Tri-Specific T Cell Engager ...
Frontiers | Advances in DLL3-targeted therapies for small cell lung ...
Harpoon Therapeutics (HARP) Stock Price, News, Quotes-Moomoo
Is It The Rise Of Clinical Stage Pharma Small Caps? Decoding The ...
Slide 28
Merck to Acquire Harpoon Therapeutics in Deal Valued at $680 Million ...
Merck, Onkoloji Hattını Harpoon Therapeutics’i Satın Alarak ...
Structural and functional insights into CD3 bispecific antibodies ...
Discover the power of VHHs for faster antibody discovery
癌症治疗中的新兴抗体 来源：药渡撰文：五月 编辑：丸子抗体领域无疑是近几年最火的研发领域，不论是从融资金额，融资数量，获批药物数量还是从抗体药 ...
Full article: Antibody-Based Therapeutics in Small Cell Lung Cancer: A ...
Slide 37
.jpg)
.png)
